BUZZ-Exane sees slow recovery for chemicals

Reuters01-21
BUZZ-Exane sees slow recovery for chemicals

** Exane BNP Paribas says there are glimmers of hope for the ailing chemicals sector as it projects "more of a slow trot than a galloping recovery"

** Exane sees positive signs in the start of a rate-cut induced recovery of construction activity in Europe and potentially also North America

** The broker also points to a normalization of European energy prices, with the price gap between Europe and other regions back to three-year lows

** However, it expects the demand crisis and overcapacity pressures to persist for years to come

** "Without an inflection point in sight, the most likely timeframe for recovery is H2," the boker says

** The broker says it prefers shares with European construction exposure, pricing power as well as undervalued cyclicality and cuts Evonik EVKn.DE to "neutral" from "outperform" while upgrading Wacker Chemie WCHG.DE to "neutral" from "underperform"

COMPANY

NEW RATING

OLD RATING

Azelis Group

outperform

outperform

Bayer

outperform

outperform

Brenntag

neutral

neutral

CF Industries

neutral

neutral

Clariant

outperform

outperform

Evonik

neutral

outperform

IMCD

outperform

outperform

K+S

underperform

underperfrom

Lanxess

neutral

neutral

Mosaic Company

outperform

outperform

Nutrien

outperform

outperform

Umicore

neutral

neutral

Wacker Chemie

neutral

underperform

Yara

underperform

underperform

(Reporting by Simon Ferdinand Eibach)

((Simonferdinand.eibach@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment